Evidence map›Paper›PMID 38802679›Full record

ArticleDrug delivery and translational research2024

Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptors.

Jiahui Li, M Tommy Gambles, Brandt Jones, Justin A Williams, Nicola J Camp, Paul J Shami, Jiyuan Yang, Jindřich Kopeček

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiahui LiCenter for Controlled Chemical Delivery, University of Utah, 2030 East 20 South, Biopolymers Research Building, Room 205B, Salt Lake City, UT, 84112-9452, USA.
M Tommy GamblesCenter for Controlled Chemical Delivery, University of Utah, 2030 East 20 South, Biopolymers Research Building, Room 205B, Salt Lake City, UT, 84112-9452, USA.
Brandt JonesDivision of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Justin A WilliamsDivision of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Nicola J CampDivision of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Paul J ShamiDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Jiyuan YangCenter for Controlled Chemical Delivery, University of Utah, 2030 East 20 South, Biopolymers Research Building, Room 205B, Salt Lake City, UT, 84112-9452, USA. jiyuan.yang@utah.edu.
Jindřich KopečekCenter for Controlled Chemical Delivery, University of Utah, 2030 East 20 South, Biopolymers Research Building, Room 205B, Salt Lake City, UT, 84112-9452, USA. jindrich.kopecek@utah.edu.ORCID 0000-0002-4451-6944

Funding

Drug-Free Macromolecular TherapeuticsR01CA246716 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI JINDRICH H. KOPECEK, JIYUAN YANG · 2020 to 2026
$2.1M
NCI NIH HHS R01 CA246716
6 · The paper itself

Abstract

This study explores the efficacy of human serum albumin (HSA)-based Drug-Free Macromolecular Therapeutics (DFMT) in treating Chronic Lymphocytic Leukemia (CLL), a prevalent adult leukemia subtype. DFMT, a novel strategy, employs biomimetic crosslinking of CD20 and CD38 receptors on malignant B cells without the need for low molecular weight drugs. Apoptosis is initiated via a two-step process: i) Recognition of a bispecific engager, Fab' fragment conjugated with morpholino oligonucleotide (Fab'-MORF1), by a cell surface antigen; followed by ii) crosslinking of the MORF1-decorated cells with a multivalent effector, HSA holding multiple copies of complementary MORF2, HSA-(MORF2)x. Herein we evaluated the efficacy of HSA-based DFMT in the treatment of 56 samples isolated from patients diagnosed with CLL. Fab' fragments from Obinutuzumab (OBN) and Isatuximab (ISA) were employed in the synthesis of anti-CD20 (Fab'

Indexed as

ADP-ribosyl Cyclase 1Antibodies, Monoclonal, HumanizedAntigens, CD20ApoptosisLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic AgentsCell Line, TumorCross-Linking ReagentsHumansImmunoglobulin Fab FragmentsMembrane GlycoproteinsSerum Albumin, HumanADP-ribosyl Cyclase 1Antibodies, Monoclonal, HumanizedAntigens, CD20Antineoplastic AgentsCD38 protein, humanCross-Linking ReagentsImmunoglobulin Fab FragmentsisatuximabMembrane GlycoproteinsobinutuzumabSerum Albumin, HumanApoptosisCD20CD38Chronic lymphocytic leukemiaDrug-free macromolecular therapeuticsReceptor crosslinking

Identifiers

PMID38802679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.